Results 141 to 150 of about 455,027 (266)

B-Cell Lymphomas

, 2020
Subramanian Kalaivani Selvi, B.H. Srinivas, Sadhanandham Shrinuvasan   +2 more
openaire   +3 more sources

Integrated Clinical and Proteomic Profiling of CD19 Chimeric Antigen Receptor T Cell Therapy in Progressive Systemic Sclerosis

Arthritis &Rheumatology, EarlyView.
Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia, Wanyi Lin, Zhangyi Zhao, Fenglin Wu, Chaoyu Gu, Yuankai Sun, Zhe Ding, Chang Wei, Xinyu Li, Cuiwei Xie, Peng Xia, Zhen Xia, Xuesong Liu, Shaoying Yang, Chunyan Zhang, Hanlin Yin, Liangjing Lu   +16 more
wiley   +1 more source

A case of transformation of Waldenström's Macroglobulinemia to diffuse large B cell lymphoma. [PDF]

Oxf Med Case Reports
Ali MB, Kline K.
europepmc   +1 more source

Homocitrullinated Peptides Drive Pro‐Inflammatory T Cell Responses in a Humanized Mouse Model of Rheumatoid Arthritis

Arthritis &Rheumatology, EarlyView.
Objective Anti‐homocitrullinated protein/peptide antibodies are specific to rheumatoid arthritis (RA) and predictive of worse prognosis, suggesting a pathogenic role for autoreactivity to homocitrullinated peptides (HomoCitP). However, T cell responses to HomoCitP remain largely unexplored.
Sofya Ulanova, Jaspreet Kaur, Gabrielle Buckley, S. M. Mansour Haeryfar, Lisa Cameron, Ewa Cairns, Lillian Barra   +6 more
wiley   +1 more source

Mechanisms of first-line treatment resistance in diffuse large B-cell lymphoma. [PDF]

Front Immunol
Zhan Z, Li P, Liu Y, Zhen C, Zhang Y, Bai O.   +5 more
europepmc   +1 more source

[Radioimmunotherapy for B-cell lymphoma].

[Rinsho ketsueki] The Japanese journal of clinical hematology, 2006
openaire   +2 more sources

Distinct molecular pathways supporting Sjögren's Disease clusters and disease progression.

Arthritis &Rheumatology, Accepted Article.
Objective Sjögren's disease (SjD) is a heterogeneous autoimmune disease. We aimed to investigate blood transcriptomic signatures and disease progression among three recently defined SjD patient clusters: (1) B‐cell active with low symptoms (BALS), (2) high systemic activity (HSA), and (3) low systemic activity with high symptoms (LSAHS).
Sacha E Silva‐Saffar, Yann Nguyen, Raphaèle Seror, Jacques‐Eric Gottenberg, Anna Niarakis, Xavier Mariette, Gaetane Nocturne   +6 more
wiley   +1 more source

Current treatment algorithm: diffuse large B cell lymphoma. [PDF]

Blood Cancer J
Ansell SM, Nowakowski GS.
europepmc   +1 more source

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia—A comprehensive review

British Journal of Clinical Pharmacology, EarlyView.
While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis, Leiah J. Brigitha, Lidwien M. Hanff, Alwin D. R. Huitema, Inge M. van der Sluis, Meta H. M. Diekstra   +5 more
wiley   +1 more source

Clonal analysis of a case with fluid overload-associated large B-cell lymphoma evolving from primary large B-cell lymphoma of the central nervous system. [PDF]

Ann Hematol
Ito Y, Kogure Y, Maeshima AM, Hosoba R, Fukuhara S, Munakata W, Chiba K, Okada A, Shiraishi Y, Narita Y, Izutsu K, Kataoka K.   +11 more
europepmc   +1 more source